Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,130.99 -29.32 -1.36%
FTSE 100 5,342.77 -48.37 -0.90%
DAX 6,339.19 -57.65 -0.90%
Ticker Volume Price Price Delta
Nikkei 8,633.19 -23.89 -0.28%
TOPIX 723.62 -3.41 -0.47%
Hang Seng 18,660.20 -395.25 -2.07%
Gold 1,549.30 -0.11%
EUR-USD 1.2464 -0.3077%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,342.77 -0.90%
STOXX 50 2,130.99 -1.36%
DAX 6,339.19 -0.90%
Oil (WTI) 89.98 -0.86%
U.S. 10-year 1.711% -0.036
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: Toronto
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

QLT:CN

7.7400 CAD 0.1800 2.27%

As of 15:59:59 ET on 05/29/2012.

Snapshot for QLT Inc (QLT)

Open: 7.8200 Day's Range: 7.6300 - 7.8600 Volume: 18,492 Bid: 7.7300
Previous Close: 7.9200 52wk Range: 5.3400 - 8.0000 1-Yr Rtn: +6.76% Ask: 7.7900

Stock Chart for QLT

No chart data available.
  • QLT:CN 7.7400
  • 1D
  • 1M
  • 1Y
7.9200
Interactive QLT Chart

Previous Close

Key Statistics for QLT

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -0.7700
Est. EPS (USD) (12/2012) -1.0070
Est. PEG Ratio -
Market Cap (M CAD) 379.81
Shares Outstanding (M) 49.07
Enterprise Value (M USD) (ttm) 163.17
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 1.1571
Price/Sale (ttm) 8.8542
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 07/27/2012
More QLT Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for QLT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More QLT Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More QLT Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More QLT Cash Flow Data

Company Profile & Key Executives for QLT

QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The Company's lead drug, Visudyne, is marketed by Novartis AG, and is used in the treatment of the wet form of age-related macular degeneration.

C Boyd ClarkeChairmanRobert L Butchofsky "Bob"President/CEO
Linda M LupiniSenior VP:Human ResourcesAlexander R LussowSenior VP:Business Development
More Company Profile & Key Executives for QLT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements